For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Centene (CNC) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Centene is one of 916 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Centene is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for CNC's full-year earnings has moved 42.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, CNC has moved about 57.9% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 2.3% on a year-to-date basis. As we can see, Centene is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Alzamend Neuro, Inc. (ALZN). The stock has returned 6.6% year-to-date.
Over the past three months, Alzamend Neuro, Inc.'s consensus EPS estimate for the current year has increased 59.6%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Centene belongs to the Medical - HMOs industry, a group that includes 7 individual stocks and currently sits at #32 in the Zacks Industry Rank. On average, this group has gained an average of 16.3% so far this year, meaning that CNC is performing better in terms of year-to-date returns.
On the other hand, Alzamend Neuro, Inc. belongs to the Medical - Biomedical and Genetics industry. This 437-stock industry is currently ranked #165. The industry has moved +7% year to date.
Centene and Alzamend Neuro, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Centene Corporation (CNC): Free Stock Analysis Report
Alzamend Neuro, Inc. (ALZN): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).